UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 241

Sortiert nach

Integrating patient-centered factors in the risk assessment of MDS

Hematology, 2019-12, Vol.2019 (1), p.373-380

Buckstein, Rena J

2019

Link zum Volltext

Verfügbarkeit prüfen

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

The New England journal of medicine, 2020-01, Vol.382 (2), p.140-151

2020

Link zum Volltext

Verfügbarkeit prüfen

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2670-2677

2012

Link zum Volltext

Verfügbarkeit prüfen

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

Nature medicine, 2010-01, Vol.16 (1), p.49-58

2010

Link zum Volltext

Verfügbarkeit prüfen

Predictors of intensive care unit admission in patients with hematologic malignancy

Scientific reports, 2020-12, Vol.10 (1), p.21145-21145, Article 21145

2020

Link zum Volltext

Verfügbarkeit prüfen

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

Blood, 2012-10, Vol.120 (16), p.3280-3287

2012

Link zum Volltext

Verfügbarkeit prüfen

Previously unreported WRAP53 gene variants in a patient with dyskeratosis congenita

Annals of hematology, 2022-04, Vol.101 (4), p.907-909

2022

Link zum Volltext

Verfügbarkeit prüfen

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

Journal of clinical oncology, 2009-08, Vol.27 (23), p.3842-3848

2009

Link zum Volltext

Verfügbarkeit prüfen

Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis

Blood advances, 2019-08, Vol.3 (16), p.2482-2486

2019

Link zum Volltext

Verfügbarkeit prüfen

Predictors of delay in diagnosis and treatment in diffuse large B‐cell lymphoma and impact on survival

British journal of haematology, 2015-02, Vol.168 (4), p.492-500

2015

Link zum Volltext

Verfügbarkeit prüfen

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes

Haematologica (Roma), 2023-02, Vol.108 (2), p.532-542

2023

Link zum Volltext

Verfügbarkeit prüfen

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)

Haematologica (Roma), 2016-06, Vol.101 (6), p.781-788

2016

Link zum Volltext

Verfügbarkeit prüfen

P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e34230b4

2023

Link zum Volltext

Verfügbarkeit prüfen

The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes

Annals of hematology, 2022-05, Vol.101 (5), p.1023-1030

2022

Link zum Volltext

Verfügbarkeit prüfen

Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group

Journal of clinical oncology, 2013-03, Vol.31 (9), p.1164-1171

2013

Link zum Volltext

Verfügbarkeit prüfen

Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review

PloS one, 2021-03, Vol.16 (3), p.e0249087-e0249087

2021

Link zum Volltext

Verfügbarkeit prüfen

Outpatient transfusions: time to study what matters to patients

Transfusion (Philadelphia, Pa.), 2019-06, Vol.59 (6), p.1887-1890

2019

Link zum Volltext

Verfügbarkeit prüfen

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

Clinical cancer research, 2006-09, Vol.12 (17), p.5190-5198

2006

Link zum Volltext

Verfügbarkeit prüfen

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes

iScience, 2022-10, Vol.25 (10), p.104931-104931, Article 104931

2022

Link zum Volltext

Verfügbarkeit prüfen

Eltrombopag use in higher risk myeloid cancers: fitting a square “pag” into a round hole?

The Lancet. Haematology, 2019-03, Vol.6 (3), p.e111-e112

Buckstein, Rena

2019

Link zum Volltext

Verfügbarkeit prüfen

P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY‐FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7, p.n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Involvement of Multiple Signaling Pathways in Follicular Lymphoma Transformation: p38-Mitogen-Activated Protein Kinase as a Target for Therapy

Proceedings of the National Academy of Sciences - PNAS, 2003-06, Vol.100 (12), p.7259-7264

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 241

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(236)
Mit Volltextzugriff
(218)

Publikationsform

Sprache

Englisch
(241)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(103)
Life Sciences & Biomedicine
(100)
Humans
(94)
Hematology
(75)
Oncology
(61)
Female
(51)
Male
(51)
Aged
(49)
Middle Aged
(45)
Adult
(36)
Aged, 80 And Over
(27)
Myelodysplastic Syndromes
(25)
Myelodysplastic Syndromes - Drug Therapy
(24)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Prognosis
(18)
Quality Of Life
(18)
Treatment Outcome
(18)
Myelodysplastic Syndrome
(17)
Biological And Medical Sciences
(16)
Medical Sciences
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Integrating patient-centered factors in the risk assessment of MDS

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

Predictors of intensive care unit admission in patients with hematologic malignancy

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

Previously unreported WRAP53 gene variants in a patient with dyskeratosis congenita

Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis

Predictors of delay in diagnosis and treatment in diffuse large B‐cell lymphoma and impact on survival

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)

P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA

Revised 15-item MDS-specific frailty scale maintains prognostic potential

The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes

Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group

Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review

Outpatient transfusions: time to study what matters to patients

High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes

P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES

Eltrombopag use in higher risk myeloid cancers: fitting a square “pag” into a round hole?

P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY‐FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA

Involvement of Multiple Signaling Pathways in Follicular Lymphoma Transformation: p38-Mitogen-Activated Protein Kinase as a Target for Therapy

Suchergebnisse filtern